MétaCan
Menu
Back to cohort
Record W4410151794 · doi:10.1101/2025.05.04.25326946

The trials of interpreting clinical trials - A Bayesian perspective Colchicine in secondary cardiovascular prevention

2025· preprint· en· W4410151794 on OpenAlexaff
James M. Brophy

Bibliographic record

VenuemedRxiv · 2025
Typepreprint
Languageen
FieldImmunology and Microbiology
Topicinterferon and immune responses
Canadian institutionsMcGill University Health Centre
Fundersnot available
KeywordsPerspective (graphical)Clinical trialBayesian probabilityColchicineMedicineIntensive care medicineInternal medicineComputer scienceArtificial intelligence

Abstract

fetched live from OpenAlex

Abstract Objectives Evidence based medicine (EBM) places systematic reviews and meta-analyses, at the top of the evidential pyramid. Bayesian methods may assist in better understanding uncertainties and improve interpretations and harmonization. Design A 2022 meta-analysis concluded that colchicine reduced the cardiac risk in secondary prevention. Nevertheless, a large, RCT (CLEAR) continued to randomize acute patients to colchicine or placebo and in 2025 published their findings of no benefit. Bayesian sequential analyses and hierarchical meta-analysis can inform the decision to complete this trial and augment the nuances surrounding its interpretation. Setting RCTs of coronary artery disease (CAD) patients with an acute coronary syndrome admission undergoing percutaneous coronary intervention (PCI). Interventions Randomization to colchicine or placebo. Main outcomes The primary outcome was major adverse cardiovascular events (MACE), a composite of death from cardiovascular causes, recurrent myocardial infarction, stroke, or unplanned ischemia-driven coronary revascularization. Results A published 2022 meta-analysis suggested a statistical MACE decrease with colchicine (RR 0.73 [95% confidence interval (CI) 0.62, 0.86]), but a Bayesian reanalysis showed a 95% credible interval (95% CrI 0.26, 1.70) for the next study, justifying continuing the CLEAR tiral. CLEAR results were eventually interpreted as “negative” (HR, 0.99; 95% confidence interval [CI], 0.85 to 1.16). Bayesian sequential re-analyses using a vague prior (i..e. result dominated by CLEAR), an all-inclusive prior (based on the previous meta-analysis), and a focused prior (considering only the largest and most similar previous RCT) showed 58%, 100% and 92% probabilities respectively of a MACE decrease with colchicine. The probabilities of clinically meaningful decreased, based on > absolute 15% MACE reduction, were more modest, between 2% - 41%. Conclusions Bayesian analyses offer advantages in clinical trial design and interpretation. The worked example strongly suggests some benefit for colchicine in secondary cardiovascular prevention, but it is unlikely to be of clinical importance.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.567
metaresearch head score (Gemma)0.811
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesMetaresearch
Consensus categoriesMetaresearch
DomainCandidate signal: Methods · Consensus signal: Methods
Study designCandidate signal: Theoretical or conceptual · Consensus signal: Theoretical or conceptual
GenreCandidate signal: Commentary · Consensus signal: Commentary
Teacher disagreement score0.433
Threshold uncertainty score0.534

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.5670.811
Meta-epidemiology (narrow)0.0040.004
Meta-epidemiology (broad)0.0130.006
Bibliometrics0.0140.009
Science and technology studies0.0030.024
Scholarly communication0.0170.016
Open science0.0090.007
Research integrity0.0150.019
Insufficient payload (model declined to judge)0.0050.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.096
GPT teacher head0.433
Teacher spread0.337 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; the direct Gemma label and the distilled Codex classifier agree on what is shown here.

Study designTheoretical or conceptual
DomainMethods
GenreCommentary

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venuemedRxivSame topicinterferon and immune responsesFrench-language works237,207